Table 3. Effects of 4 weeks linagliptin treatment in C57BL/6N mice after 3 months of HFD (study 2; n = 15 per experimental group) on GLP-1 serum concentrations, food intake, body weight, fed glucose levels, HbA1c and liver triglyceride content.
| GLP-1 (pM) | Food intake(g/day) | Body weight (g) | Glucose (mM) | HbA1c (%) | Liver TG (µg/mg) | |
| Vehicle | ND | 2.8±0.3 | 44.4±0.5 | 6.2±0.1 | 4.6±0.03 | 60.7±3.2 |
| Linagliptin 3 mg/kg/day | 18.4±4.0 | 3.1±0.2 | 44.3±0.7 | 5.8±0.8*** | 4.3±0.03*** | 47.9±2.4*** |
| Linagliptin 30 mg/kg/day | 26.4±3.7 | 3.1±0.4 | 44.7±1.6 | 5.7±0.07*** | 4.3±0.03*** | 39.1±2.4*** |
| Chow fed | 7.5±3.4 | 4.0±0.3 | 25.2±0.5 | 5.7±0.08*** | 4.3±0.03*** | 14.3±0.9*** |
Values are given as mean ± SEM. ***P<0.001 compared with vehicle-treated DIO mice.
GLP-1, glucagon-like peptide-1; HbA1c, glycated hemoglobin; HFD, high-fat diet; ND, not detectable; TG, triglycerides.